- Home
- CLM vs ADPT Comparison
CLM vs ADPT Comparison
Compare CLM & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLM
- ADPT
- Stock Information
- Founded
- CLM 1987
- ADPT 2009
- Country
- CLM United States
- ADPT United States
- Employees
- CLM N/A
- ADPT N/A
- Industry
- CLM Finance/Investors Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLM Finance
- ADPT Health Care
- Exchange
- CLM Nasdaq
- ADPT Nasdaq
- Market Cap
- CLM 2.3B
- ADPT 2.6B
- IPO Year
- CLM N/A
- ADPT 2019
- Fundamental
- Price
- CLM $8.27
- ADPT $19.62
- Analyst Decision
- CLM
- ADPT Strong Buy
- Analyst Count
- CLM 0
- ADPT 10
- Target Price
- CLM N/A
- ADPT $16.60
- AVG Volume (30 Days)
- CLM 1.4M
- ADPT 2.5M
- Earning Date
- CLM 01-01-0001
- ADPT 11-05-2025
- Dividend Yield
- CLM 18.74%
- ADPT N/A
- EPS Growth
- CLM N/A
- ADPT N/A
- EPS
- CLM N/A
- ADPT N/A
- Revenue
- CLM N/A
- ADPT $252,754,000.00
- Revenue This Year
- CLM N/A
- ADPT $36.43
- Revenue Next Year
- CLM N/A
- ADPT $12.31
- P/E Ratio
- CLM N/A
- ADPT N/A
- Revenue Growth
- CLM N/A
- ADPT 42.57
- 52 Week Low
- CLM $6.25
- ADPT $5.29
- 52 Week High
- CLM $8.84
- ADPT $20.76
- Technical
- Relative Strength Index (RSI)
- CLM 53.78
- ADPT 67.55
- Support Level
- CLM $7.95
- ADPT $13.28
- Resistance Level
- CLM $8.23
- ADPT $20.76
- Average True Range (ATR)
- CLM 0.11
- ADPT 1.12
- MACD
- CLM 0.00
- ADPT 0.58
- Stochastic Oscillator
- CLM 75.00
- ADPT 84.89
About CLM Cornerstone Strategic Value Fund Inc. New
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, utilities, energy, telecommunication services, materials, and other sectors.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).